XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Other Assets | 9 Months Ended
--- | ---
Jun. 30, 2018
Investments All Other Investments [Abstract] |
Other Assets | 7. Other Assets Other assets consist of the following:
|  | June 30, |  |  | September 30, |
(Dollars in thousands) |  | 2018 |  |  | 2017 |
ViaCyte, Inc. |  | $ | 479 |  |  | $ | 479 |
Other noncurrent assets |  |  | 1,143 |  |  |  | 418 |
Other assets, net |  | $ | 1,622 |  |  | $ | 897 |
The Company has invested a total of $5.3 million in ViaCyte, Inc. (“ViaCyte”), a privately-held California-based biotechnology firm that is developing a unique treatment for diabetes using coated islet cells, the cells that produce insulin in the human body. The balance of the investment of $0.5 million, which is net of previously recorded other-than-temporary impairments of $4.8 million, is accounted for under the cost method and represents less than a 1% ownership interest. The Company does not exert significant influence over ViaCyte’s operating or financial activities. The carrying value of each cost method investment is reviewed quarterly for changes in circumstances or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investment.

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAllOtherInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for investments and other noncurrent assets. + References No definition available. + Details
Name: | us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration